Universitätspublikationen
Refine
Year of publication
Document Type
- Article (4884)
- Doctoral Thesis (776)
- Part of Periodical (178)
- Preprint (164)
- Conference Proceeding (121)
- Book (79)
- Contribution to a Periodical (63)
- Review (27)
- Part of a Book (16)
- Working Paper (8)
Language
Keywords
- inflammation (76)
- COVID-19 (59)
- SARS-CoV-2 (48)
- glioblastoma (38)
- cancer (37)
- apoptosis (36)
- Inflammation (35)
- breast cancer (34)
- autophagy (29)
- prostate cancer (28)
Institute
- Medizin (6330) (remove)
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1+/+ and Tax1BP1−/− mice. The amount and subsets of non-parenchymal liver cells in in Tax1BP1+/+ and Tax1BP1−/− mice were determined and activation of NFκB and stress induced signaling pathways were assessed. Differential expression of mRNA and miRNA was determined. Tax1BP1−/− mice showed increased numbers of inflammatory cells in the liver. Furthermore, a sustained activation of the NFκB signaling pathway was found in hepatocytes as well as increased transcription of proinflammatory cytokines in isolated Kupffer cells from Tax1BP1−/− mice. Several differentially expressed mRNAs and miRNAs in livers of Tax1BP1−/− mice were found, which are regulators of inflammation or are involved in cancer development or progression. Furthermore, Tax1BP1−/− mice developed more HCCs than their Tax1BP1+/+ littermates. We conclude that Tax1BP1 protects from liver cancer development by limiting proinflammatory signaling.
Die Pathophysiologie der Bandscheibendegeneration (intervertebral disc degeneration, IVDD) und ihre molekularen Mechanismen sind noch in weiten Teilen unverstanden. Ihre Ursachen und Risikofaktoren sind vielfältig und schließen unter anderem Alter, Geschlecht, Umwelteinflüsse oder mechanische Belastungen mit ein.
Für das der Bandscheibe eng verwandte Knorpelgewebe wurde in aktuellen Studien der Einfluss des Sympathikus bzw. dessen Neurotransmitters Noradrenalin (NE) via adrenerger Rezeptoren (AR) auf die Zellproliferation, die Expression von Molekülen der extrazellulären Matrix und somit auch auf die Degeneration beschrieben. In Bandscheiben wurde bereits das Vorhandensein von sympathischen Nervenendigungen nachgewiesen, allerdings wurde die Expression der Adrenozeptoren hier noch nie untersucht. Das Ziel der vorliegenden Arbeit war also die Analyse der ARs im Gewebe der Bandscheibe und die Evaluation der Korrelation mit der Bandscheibendegeneration.
Das für die Analyse benötigte Gewebe stammt von Patienten, bei welchen eine Wirbelkörperverblockung (Spondylodese) durchgeführt wurde. Im Rahmen dieser Spondylodese wird das Bandscheibengewebe des betroffenen Segmentes entfernt. Der Degenerationsgrad der anonymisierten Proben wurde prä- und intraoperativ bestimmt und im entnommenen Gewebe sowie in isolierten Zellen die Expression aller bekannten ARs mittels reverse transcription polymerase chain reaction (RT-PCR) untersucht. Zum Nachweis der ARs auf Proteinebene wurden einzelne humane Proben auch immunhistochemisch analysiert. Des Weiteren wurde anhand von Wildtyp- und sogenannten SM/J-Mäusen, die eine spontane IVDD entwickeln, die Proteinexpression der ARs und der extrazellulären Matrix (ECM) von gesunden und geschädigten Bandscheiben an histologischen Schnitten verglichen. Schließlich wurde an isolierten und kultivierten humanen Zellen ein Stimulationsversuch mit Noradrenalin durchgeführt, um zu prüfen, ob es nach Aktivierung der ARs zu einer intrazellulären Signalweiterleitung kommt.
In Nativgewebe der humanen Bandscheibe konnte die messenger Ribonukleinsäure (mRNA) von α1a-, α1b-, α2a-, α2b-, α2c-, β1- und β2-ARs nachgewiesen werden. Nach siebentägiger Zellkultur im Monolayer präsentierte sich ein nur dezent abweichendes Genexpressionsmuster. Auf Proteinebene war das Signal des β2-AR nur im Bereich des Annulus fibrosus (AF) detektierbar jedoch nicht im Nucleus pulposus (NP). Selbiges war auch in murinen Schnitten festzustellen, wobei sich bei Wildtype (WT)-Mäusen hauptsächlich im inneren AF β2-positive Zellen fanden, während sich das Signal bei der SM/J-Maus weiter in Richtung des äußeren AF und des NP ausdehnte. α2a-AR und α2c-AR waren hingegen auf Proteinebene nicht nachweisbar. Bei der immunhistochemischen Untersuchung relevanter ECM-Moleküle zeigte sich für Kollagen II, Kollagen XII, cartilage oligomeric matrix protein (COMP) und Decorin (DCN) eine Verteilung, die mit der des β2-AR-Signals korreliert. Der Stimulationsversuch in humaner Zellkultur ergab eine Aktivierung der für die ARs relevanten Proteinkinase A (PKA)- und extracellular signal–regulated kinases (ERK1/2) -Signalwege.
In der vorliegenden Arbeit konnte zum ersten Mal die Existenz und Funktionalität von Adrenozeptoren im Bandscheibengewebe nachgewiesen werden. Unterschiede in der Expression der ARs, kombiniert mit Veränderungen der ECM-Zusammensetzung könnten ein Hinweis auf den Einfluss des Sympathikus bei IVDD sein. Die aktuelle demographische Entwicklung und die sich hieraus ergebende gesundheitsökonomische Belastung machen die Ergründung molekularer Mechanismen der IVDD und die daraus resultierende Entwicklung innovativer Behandlungsmethoden zu Kardinalfragen moderner orthopädischer Grundlagenforschung.
Healthy and degenerating intervertebral discs (IVDs) are innervated by sympathetic nerves, however, adrenoceptor (AR) expression and functionality have never been investigated systematically. Therefore, AR gene expression was analyzed in both tissue and isolated cells from degenerated human IVDs. Furthermore, human IVD samples and spine sections of wildtype mice (WT) and of a mouse line that develops spontaneous IVD degeneration (IVDD, in SM/J mice) were stained for ARs and extracellular matrix (ECM) components. In IVD homogenates and cells α1a-, α1b-, α2a-, α2b-, α2c-, β1-, and β2-AR genes were expressed. In human sections, β2-AR was detectable, and its localization parallels with ECM alterations. Similarly, in IVDs of WT mice, only β2-AR was expressed, and in IVDs of SM/J mice, β2AR expression was stronger accompanied by increased collagen II, collagen XII, decorin as well as decreased cartilage oligomeric matrix protein expression. In addition, norepinephrine stimulation of isolated human IVD cells induced intracellular signaling via ERK1/2 and PKA. For the first time, the existence and functionality of ARs were demonstrated in IVD tissue samples, suggesting that the sympathicus might play a role in IVDD. Further studies will address relevant cellular mechanisms and thereby help to develop novel therapeutic options for IVDD.
Recent data have suggested that performing recanalizing therapies in ischemic stroke might lead to an increased risk of acute symptomatic seizures. This applies to both intravenous thrombolysis and mechanical thrombectomy. We therefore determined the frequency of acute symptomatic seizures attributable to these two recanalization therapies using a large, population-based stroke registry in Central Europe. We performed two matched 1:1 case–control analyses. In both analyses, patients were matched for age, stroke severity on admission and pre-stroke functional status. The first analysis compared patients treated with intravenous thrombolysis to a non-recanalization control group. To isolate the effect of mechanical thrombectomy, we compared patients with both mechanical thrombectomy and intravenous thrombolysis to those with only intravenous thrombolysis treatment in a second analysis. From 135,117 patients in the database, 13,356 patients treated with only intravenous thrombolysis, and 1013 patients treated with both intravenous thrombolysis and mechanical thrombectomy were each matched to an equivalent number of controls. Patients with intravenous thrombolysis did not suffer from clinically apparent acute symptomatic seizures significantly more often than non-recanalized patients (treatment = 199; 1.5% vs. control = 237; 1.8%, p = 0.07). Mechanical thrombectomy in addition to intravenous thrombolysis also was not associated with an increased risk of acute symptomatic seizures, as the same number of patients suffered from seizures in the treatment and control group (both n = 17; 1.7%, p = 1). In a large population-based stroke registry, the frequency of clinically apparent acute symptomatic seizures was not increased in patients who received either intravenous thrombolysis alone or in conjunction with mechanical thrombectomy.
Introduction: Affective disorders are a major global burden, with approximately 15% of people worldwide suffering from some form of affective disorder. In patients experiencing their first depressive episode, in most cases it cannot be distinguished whether this is due to bipolar disorder (BD) or major depressive disorder (MDD). Valid fluid biomarkers able to discriminate between the two disorders in a clinical setting are not yet available.
Material and Methods: Seventy depressed patients suffering from BD (bipolar I and II subtypes) and 42 patients with major MDD were recruited and blood samples were taken for proteomic analyses after 8 h fasting. Proteomic profiles were analyzed using the Multiplex Immunoassay platform from Myriad Rules Based Medicine (Myriad RBM; Austin, Texas, USA). Human DiscoveryMAPTM was used to measure the concentration of various proteins, peptides, and small molecules. A multivariate predictive model was consequently constructed to differentiate between BD and MDD.
Results: Based on the various proteomic profiles, the algorithm could discriminate depressed BD patients from MDD patients with an accuracy of 67%.
Discussion: The results of this preliminary study suggest that future discrimination between bipolar and unipolar depression in a single case could be possible, using predictive biomarker models based on blood proteomic profiling.
Background: A prototype of a noninvasive glucometer combining skin excitation by a mid-infrared quantum cascade laser with photothermal detection was evaluated in glucose correlation tests including 100 volunteers (41 people with diabetes and 59 healthy people).
Methods: Invasive reference measurements using a clinical glucometer and noninvasive measurements at a finger of the volunteer were simultaneously recorded in five-minute intervals starting from fasting glucose values for healthy subjects (low glucose values for diabetes patients) over a two-hour period. A glucose range from >50 to <350 mg/dL was covered. Machine learning algorithms were used to predict glucose values from the photothermal spectra. Data were analyzed for the average percent disagreement of the noninvasive measurements with the clinical reference measurement and visualized in consensus error grids.
Results: 98.8% (full data set) and 99.1% (improved algorithm) of glucose results were within Zones A and B of the grid, indicating the highest accuracy level. Less than 1% of the data were in Zone C, and none in Zone D or E. The mean and median percent differences between the invasive as a reference and the noninvasive method were 12.1% and 6.5%, respectively, for the full data set, and 11.3% and 6.4% with the improved algorithm.
Conclusions: Our results demonstrate that noninvasive blood glucose analysis combining mid-infrared spectroscopy and photothermal detection is feasible and comparable in accuracy with minimally invasive glucometers and finger pricking devices which use test strips. As a next step, a handheld version of the present device for diabetes patients is being developed.
Obstructive Sleep Apnea is emerging as a global health epidemic, particularly due to the obesity pandemic. However, comprehensive prevalence data are still lacking and global OSA research has not yet been structurally evaluated. Using the latest comprehensive age/gender-specific BMI and obesity data, a global landscape estimating the risk/burden of OSA was created. Results were presented in relation to an in-depth analysis of OSA research and countries’ socioeconomic/scientific background. While the USA, Canada, and Japan are the highest publishing countries on OSA, Iceland, Greece, and Israel appeared at the forefront when relating the scientific output to socioeconomic parameters. Conversely, China, India, and Russia showed relatively low performances in these relations. Analysis of the estimated population at risk (EPR) of OSA showed the USA, China, India, and Brazil as the leading countries. Although the EPR and OSA research correlated strongly, major regional discrepancies between the estimated demand and actual research performances were identified, mainly in, but not limited to, developing nations. Our study highlights regional challenges/imbalances in the global activity on OSA and allows targeted measures to mitigate the burden of undiagnosed/untreated OSA. Furthermore, the inclusion of disadvantaged countries in international collaborations could stimulate local research efforts and provide valuable insights into the regional epidemiology of OSA.
Background: Fabry disease (FD), the second most prevalent lysosomal storage disorder, is classified as a rare disease. It often leads to significant quality of life impairments and premature death. Many cases remain undiagnosed due to the rarity and heterogeneity. Further, costs related to treatment often constitute a substantial financial burden for patients and health systems. While its epidemiology is still unclear, newborn screenings suggest that its actual prevalence rate is significantly higher than previously suspected. Methods: Based on well-established methodologies, this study gives an overview about the background of the development of FD-related research and provides a critical view of future needs. Results: On the grounds of benchmarking findings, an increasing research activity on FD can be observed. Most publishing countries are the USA, some European countries, Japan, Taiwan, and South Korea. In general, high-income countries publish comparably more on FD than low- or middle-income economies. The countries' financial and infrastructural background are unveiled as crucial factors for the FD research activity. Conclusions: Overall, there is a need to foster FD research infrastructure in developing and emerging countries with focus on cost-intensive genetic research that is independent from economic interests of big pharmaceutical companies.
Working memory (WM) performance varies substantially among individuals but the precise contribution of different WM component processes to these functional limits remains unclear. By analyzing different types of responses in a spatial WM task, we recently demonstrated a functional dissociation between confident and not-confident errors reflecting failures of WM encoding and maintenance, respectively. Here, we use event-related brain potentials to further explore this dissociation. Healthy participants performed a delayed orientation-discrimination task and rated their response confidence for each trial. The encoding-related N2pc component was significantly reduced for confident errors compared to confident correct responses, which is indicative of an encoding failure. In contrast, the maintenance-related contra-lateral delay activity was similar for these response types indicating that in confident error trials, WM representations – potentially the wrong ones – were maintained accurately and with stability throughout the delay interval. However, contra-lateral delay activity measured during the early part of the delay period was decreased for not-confident errors, potentially reflecting compromised maintenance processes. These electrophysiological findings contribute to a refined understanding of the encoding and maintenance processes that contribute to limitations in WM performance and capacity.
Cancer‐associated venous thromboembolism (VTE) is a frequent, potentially life‐threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer‐associated thrombosis (CAT); factor Xa–inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low‐molecular‐weight heparin for the treatment of CAT indicated that DOACs are efficacious in this setting, with findings reflected in recent updates to published guidance on CAT treatment. However, the higher risk of bleeding events (particularly in the gastrointestinal tract) with DOACs highlights the need for appropriate patient selection. Further insights will be gained from additional studies that are ongoing or awaiting publication. The efficacy and safety of DOAC thromboprophylaxis in ambulatory patients with cancer at a high risk of VTE have also been assessed in placebo‐controlled randomized controlled trials of apixaban and rivaroxaban. Both studies showed efficacy benefits with DOACs, but both studies also showed a nonsignificant increase in major bleeding events while on treatment. This review summarizes the evidence base for rivaroxaban use in CAT, the patient profile potentially most suited to DOAC use, and ongoing controversies under investigation. We also describe ongoing studies from the CALLISTO (Cancer Associated thrombosis—expLoring soLutions for patients through Treatment and Prevention with RivarOxaban) program, which comprises several randomized clinical trials and real‐world evidence studies, including investigator‐initiated research.